Selective OXT analogs are a promising therapeutic avenue for obesity as they could provide a longer duration of action to increase efficacy and selectivity to the OXT receptor to avoid unwanted off-target effects. This evidence concerns the gene OXT and obesity due to melanocortin 4 receptor deficiency.